|By PR Newswire||
|January 16, 2014 07:09 AM EST||
NEW YORK, Jan. 16, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022
PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022
The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.
Treatment options in China are extremely limited compared with the 7MM. Although some recombinant replacement therapies for hemophilia A and B, such as Recombinate, Xyntha, Kogenate, Advate and BeneFIX, are approved for marketing in China, they are not covered by national or provisional insurance programs and access to these drugs is extremely limited.
- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China Hemophilia A and B market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis and Quality of Life 16
3.2 Symptoms 17
3.2.1 Hemophilia A and B 17
3.2.2 Inhibitors 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Hemophilia A and B Diagnosis 20
4.1.2 Hemophilia A and B Treatment 20
4.1.3 Inhibitors Diagnosis 22
4.1.4 Inhibitors Treatment 22
4.2 China 24
4.2.1 Clinical Practice 24
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitive Assessment 27
5.3 Product Profiles - Major Brands, Hemophilia A 31
5.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 31
5.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 35
5.3.3 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 38
5.4 Product Profiles - Hemophilia B 40
5.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 40
5.4.2 Rixubis (BAX-326) 43
5.5 Product Profiles - Hemophilia A and B with Inhibitors 46
5.5.1 NovoSeven RT (coagulation factor VIIa [recombinant]) 46
6 Opportunity and Unmet Need 48
6.1 Overview 48
6.2 Opportunities Analysis 49
6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections 49
6.2.2 Lower-Cost Recombinant Replacement Therapies 50
6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 51
6.2.4 More Convenient Drug Administration 51
6.2.5 Oral Formulation of Recombinant Replacement Therapies 52
6.3 Unmet Needs Gap Analysis 52
6.3.1 Long-Acting FVIII Replacement Therapies 52
6.3.2 Gene Therapy Treatments for Hemophilia A and B 53
7 Pipeline Assessment 54
7.1 Overview 54
7.2 Promising Drugs in Clinical Development - Hemophilia A 54
7.2.1 BAY 94-9027 (octocog alfa) 56
7.2.2 BAX-855 59
7.2.3 Novoeight (turoctocog alfa; NN7008) 63
7.2.4 N8-GP (NN7088) 66
8 Market Outlook 70
8.1 China 70
8.1.1 Forecast 70
8.1.2 Key Events 73
8.1.3 Drivers and Barriers 73
9 Appendix 75
9.1 Bibliography 75
9.2 Abbreviations 83
9.3 Methodology 86
9.4 Forecasting Methodology 86
9.4.1 Diagnosed Hemophilia Patients 87
9.4.2 Percent Drug-Treated Patients 87
9.4.3 Drugs Included in Each Therapeutic Class 88
9.4.4 Launch and Patent Expiry Dates 88
9.4.5 General Pricing Assumptions 89
9.4.6 Individual Drug Assumptions 89
9.4.7 Pricing of Pipeline Agents 92
9.5 Physicians and Specialists Included in this Study 93
9.6 About the Authors 95
9.6.1 Authors 95
9.6.2 Global Head of Healthcare 96
9.7 About GlobalData 97
9.8 Disclaimer 97
1.1 List of Tables
Table 1: Symptoms of Hemophilia A and B 18
Table 2: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2013 23
Table 3: Leading Recombinant Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2013 29
Table 4: Leading Plasma-Based Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2012 30
Table 5: Product Profile - Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 32
Table 6: Advate SWOT Analysis, 2013 34
Table 7: Product Profile - Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 36
Table 8: Kogenate FS/Helixate FS SWOT Analysis, 2013 38
Table 9: Product Profile - Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 39
Table 10: Recombinate SWOT Analysis, 2013 40
Table 11: Product Profile - BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 41
Table 12: BeneFIX SWOT Analysis, 2013 42
Table 13: Product Profile - Rixubis (BAX-326) 44
Table 14: Rixubis SWOT Analysis, 2013 45
Table 15: Product Profile - NovoSeven RT (coagulation factor VIIa [recombinant]) 46
Table 16: NovoSeven RT SWOT Analysis, 2013 47
Table 17: Overall Unmet Needs - Current Level of Attainment 49
Table 18: Hemophilia A - Phase I/II Pipeline, 2013 54
Table 19: Hemophilia A - Phase III Pipeline, 2013 55
Table 20: Product Profile - BAY 94-9027 56
Table 21: BAY 94-9027 SWOT Analysis, 2013 59
Table 22: Product Profile - BAX-855 60
Table 23: BAX-855 SWOT Analysis, 2013 62
Table 24: Product Profile - Novoeight (turoctocog alfa; NN7008) 63
Table 25: Novoeight SWOT Analysis, 2013 66
Table 26: Product Profile - N8-GP (NN7088) 67
Table 27: N8-GP SWOT Analysis, 2013 69
Table 28: Sales Forecasts ($m) for Hemophilia A and B in China, 2012-2022 71
Table 29: Key Events Impacting Sales for Hemophilia A and B in China, 2013 73
Table 30: Chinese Hemophilia A and B Market - Drivers and Barriers, 2013 73
Table 31: Product Launch Dates 88
Table 32: Physicians Surveyed 93
1.2 List of Figures
Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia A, 2012-2022 55
Figure 2: Sales for Hemophilia A and B in China by Drug Class, 2012-2022 72
To order this report: PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022
Contact Clare: [email protected]
Intl: +1 339-368-6001
Between the mockups and specs produced by analysts, and resulting applications built by developers, there exists a gulf where projects fail, costs spiral, and applications disappoint. Methodologies like Agile attempt to address this with intensified communication, with partial success but many limitations. In his session at @DevOpsSummit at 19th Cloud Expo, Charles Kendrick, CTO at Isomorphic Software, will present a revolutionary model enabled by new technologies. Learn how business and deve...
Aug. 31, 2016 06:15 PM EDT Reads: 173
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Aug. 31, 2016 06:15 PM EDT Reads: 3,613
Although it has gained significant traction in the consumer space, IoT is still in the early stages of adoption in enterprises environments. However, many companies are working on initiatives like Industry 4.0 that includes IoT as one of the key disruptive technologies expected to reshape businesses of tomorrow. The key challenges will be availability, robustness and reliability of networks that connect devices in a business environment. Software Defined Wide Area Network (SD-WAN) is expected to...
Aug. 31, 2016 06:15 PM EDT Reads: 262
Developing software for the Internet of Things (IoT) comes with its own set of challenges. Security, privacy, and unified standards are a few key issues. In addition, each IoT product is comprised of (at least) three separate application components: the software embedded in the device, the back-end service, and the mobile application for the end user’s controls. Each component is developed by a different team, using different technologies and practices, and deployed to a different stack/target –...
Aug. 31, 2016 05:15 PM EDT Reads: 268
SYS-CON Events announced today that Hitrons Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Hitrons Solutions Inc. is distributor in the North American market for unique products and services of small and medium-size businesses, including cloud services and solutions, SEO marketing platforms, and mobile applications.
Aug. 31, 2016 05:00 PM EDT Reads: 872
Internet of @ThingsExpo, taking place November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 19th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devices - comp...
Aug. 31, 2016 04:45 PM EDT Reads: 3,841
SYS-CON Events announced today that Numerex Corp, a leading provider of managed enterprise solutions enabling the Internet of Things (IoT), will exhibit at the 19th International Cloud Expo | @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Numerex Corp. (NASDAQ:NMRX) is a leading provider of managed enterprise solutions enabling the Internet of Things (IoT). The Company's solutions produce new revenue streams or create operating...
Aug. 31, 2016 04:39 PM EDT Reads: 191
Enterprises have forever faced challenges surrounding the sharing of their intellectual property. Emerging cloud adoption has made it more compelling for enterprises to digitize their content, making them available over a wide variety of devices across the Internet. In his session at 19th Cloud Expo, Santosh Ahuja, Director of Architecture at Impiger Technologies, will introduce various mechanisms provided by cloud service providers today to manage and share digital content in a secure manner....
Aug. 31, 2016 04:15 PM EDT Reads: 975
We are always online. We access our data, our finances, work, and various services on the Internet. But we live in a congested world of information in which the roads were built two decades ago. The quest for better, faster Internet routing has been around for a decade, but nobody solved this problem. We’ve seen band aid approaches like CDNs that attack a niche's slice of static content part of the Internet, but that’s it. It does not address the dynamic services-based Internet of today. It doe...
Aug. 31, 2016 04:12 PM EDT Reads: 222
As the world moves toward more DevOps and Microservices, application deployment to the cloud ought to become a lot simpler. The Microservices architecture, which is the basis of many new age distributed systems such as OpenStack, NetFlix and so on, is at the heart of Cloud Foundry - a complete developer-oriented Platform as a Service (PaaS) that is IaaS agnostic and supports vCloud, OpenStack and AWS. Serverless computing is revolutionizing computing. In his session at 19th Cloud Expo, Raghav...
Aug. 31, 2016 04:00 PM EDT Reads: 1,128
While DevOps promises a better and tighter integration among an organization’s development and operation teams and transforms an application life cycle into a continual deployment, Chef and Azure together provides a speedy, cost-effective and highly scalable vehicle for realizing the business values of this transformation. In his session at @DevOpsSummit at 19th Cloud Expo, Yung Chou, a Technology Evangelist at Microsoft, will present a unique opportunity to witness how Chef and Azure work tog...
Aug. 31, 2016 03:29 PM EDT Reads: 193
As cloud adoption continues to transform business, today’s global enterprises are challenged with managing a growing amount of information living outside of the data center. The rapid adoption of IoT and increasingly mobile workforce are exacerbating the problem. Ensuring secure data sharing and efficient backup poses capacity and bandwidth considerations as well as policy and regulatory compliance issues.
Aug. 31, 2016 03:15 PM EDT Reads: 314
Why do your mobile transformations need to happen today? Mobile is the strategy that enterprise transformation centers on to drive customer engagement. In his general session at @ThingsExpo, Roger Woods, Director, Mobile Product & Strategy – Adobe Marketing Cloud, covered key IoT and mobile trends that are forcing mobile transformation, key components of a solid mobile strategy and explored how brands are effectively driving mobile change throughout the enterprise.
Aug. 31, 2016 03:00 PM EDT Reads: 790
Data is the fuel that drives the machine learning algorithmic engines and ultimately provides the business value. In his session at Cloud Expo, Ed Featherston, a director and senior enterprise architect at Collaborative Consulting, will discuss the key considerations around quality, volume, timeliness, and pedigree that must be dealt with in order to properly fuel that engine.
Aug. 31, 2016 02:30 PM EDT Reads: 2,099
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, will discuss the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports. The session will include a working demo and a technical d...
Aug. 31, 2016 02:03 PM EDT Reads: 221